Amonafide

From WikiMD's Food, Medicine & Wellness Encyclopedia

Amonafide

Amonafide[edit | edit source]

Amonafide, bearing the original designation AS1413, is an investigational drug undergoing study for its potential use in oncology. Recognized by trade names such as Quinamed and Xanafide, Amonafide emerges from the novel category of chemotherapy agents referred to as Naphthalimides. These agents function by inhibiting the topoisomerase enzyme and also intercalating DNA, leading to disruption in the replication processes of cancer cells.

Contents[edit | edit source]

Chemical Classification[edit | edit source]

Amonafide is a representative member of the Naphthalimides family of chemotherapeutic agents.

Mechanism of Action[edit | edit source]

At its core, Amonafide functions as a:

  • Topoisomerase inhibitor: By inhibiting the action of topoisomerase, Amonafide stalls the DNA replication process, halting the rapid division of cancer cells.
  • DNA intercalator: The drug wedges itself between the base pairs in the DNA structure, further hampering the DNA replication and transcription processes.

Development and Clinical Trials[edit | edit source]

Antisoma, a renowned pharmaceutical company, is at the helm of developing Amonafide as a potential anti-cancer therapy. Key milestones in its clinical development include:

  • 2008: The drug reached Phase III of clinical trials.
  • March 2010: Initiation of Phase III trial targeting secondary Acute Myeloid Leukaemia (AML).
  • June 2010: The U.S. Food and Drug Administration (FDA) conferred a Fast Track Status on Amonafide for the treatment of Secondary Acute Myeloid Leukaemia (AML).

FDA Fast Track Status[edit | edit source]

In June 2010, the FDA accorded Amonafide with a Fast Track Status. This designation is reserved for medications with the potential to address unmet medical needs, facilitating a more streamlined review process for the drug.

Potential Therapeutic Uses[edit | edit source]

While the primary focus is on harnessing Amonafide's properties to combat secondary AML, ongoing research is expected to uncover its efficacy in treating other cancer forms as well.

See Also[edit | edit source]

External links[edit | edit source]

Amonafide Resources
Doctor showing form.jpg

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".

Amonafide Resources
Doctor showing form.jpg
Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD